Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice

Digestive and Liver Disease

Volumn 44, Issue 9, 2012, Pages 788-792

  Di Costanzo, Giovan Giuseppe ^a   Tortora, Raffaella ^a   Iodice, Luca ^a   Lanza, Alfonso Galeota ^a   Lampasi, Filippo ^a   Tartaglione, Maria Teresa ^a   Picciotto, Francesco Paolo ^a   Mattera, Silvana ^a   De Luca, Massimo ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Adverse events; Hepatocellular carcinoma; Sorafenib; Targeted therapy

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CONTROL; CANCER GROWTH; COMMON TOXICITY CRITERIA VERSION 3.0; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPIGASTRIC PAIN; FATIGUE; FEMALE; HEART MUSCLE ISCHEMIA; HEPATITIS C; HOARSENESS; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; JAUNDICE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; MUSCLE CRAMP; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRIDINES;

EID: 84864397352     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.04.001     Document Type: Article

References (18)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Garcia M., Jemal A., Ward E.M., et al. Global cancer facts & figures 2007 2007, American Cancer Society. http://www.cancer.org/.
3. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
4. Sangiovanni A., Prati G.M., Fasani P., et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006, 43:1303-1310.
5. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
6. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430.
7. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, (359):378-390.
8. Cheng A.-L., Kang Y.-K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
9. European Medicines Agency. Sorafenib (Nexavar): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/nexavar/H-690-PI-en.pdf.
10. Marrero J.A., Lencioni R., Kudo M., et al. GIDEON (Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma [HCC]nd Of Its Treatment With SorafeNib) Second Interim Analysis in >1500 patients: clinical findings in patients with liver dysfunction. J Clin Oncol 2011, 29(Suppl.). [Abstract 4001].
11. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
12. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
13. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
14. Chu D., Lacouture M.E., Fillos T., et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and metaanalysis. Acta Oncol 2008, 47:176-186.
15. Vincenzi B., Santini D., Russo A., et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010, 15:85-92.
16. Je Y., Scutz F.A.B., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967-974.
17. Minor D.R. Risk of bleeding not increased by sorafenib or sunitinib. Lancet Oncol 2010, 11:112-113.
18. Norberto L., Polese L., Cillo U., et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 2007, 13:1272-1278.